{
    "hands_on_practices": [
        {
            "introduction": "Spirometry is a fundamental tool in respiratory medicine for assessing lung function. A key part of this assessment involves measuring the change in airflow after administering a bronchodilator, which helps quantify the reversible component of airway obstruction. This practice  will guide you through calculating the percentage of reversibility and applying established clinical criteria to interpret the results, a critical skill in distinguishing between asthma and some cases of Chronic Obstructive Pulmonary Disease (COPD).",
            "id": "4415583",
            "problem": "A patient with obstructive lung disease presents for spirometry before and after administration of a bronchodilator. In obstructive conditions such as asthma and chronic obstructive pulmonary disease (COPD), airflow limitation may be at least partially reversible with bronchodilation, and reversibility is assessed using changes in the forced expiratory volume in one second ($\\mathrm{FEV}_{1}$) and the forced vital capacity ($\\mathrm{FVC}$). The patient’s pre-bronchodilator values are $\\mathrm{FEV}_{1} = 1.80\\,\\mathrm{L}$ and $\\mathrm{FVC} = 3.50\\,\\mathrm{L}$. The post-bronchodilator values are $\\mathrm{FEV}_{1} = 2.06\\,\\mathrm{L}$ and $\\mathrm{FVC} = 3.78\\,\\mathrm{L}$. Use the following fundamental bases:\n- $\\mathrm{FEV}_{1}$ is the volume of air exhaled in the first second of a forced exhalation, and $\\mathrm{FVC}$ is the total volume exhaled during a forced exhalation.\n- Fractional change of a quantity is defined as the difference divided by the baseline value.\n- The American Thoracic Society/European Respiratory Society (ATS/ERS) guideline classifies a bronchodilator response as significant if the absolute increase in either $\\mathrm{FEV}_{1}$ or $\\mathrm{FVC}$ is at least $0.20\\,\\mathrm{L}$ and the relative increase (fractional change from baseline) is at least $0.12$.\n\nTasks:\n1. Compute the percent reversibility in $\\mathrm{FEV}_{1}$ and $\\mathrm{FVC}$ as dimensionless decimals using the definition of fractional change from baseline, that is, for each measure compute $\\dfrac{\\text{post} - \\text{pre}}{\\text{pre}}$.\n2. Classify the overall bronchodilator response using the ATS/ERS criterion above, encoded numerically as $C = 1$ if the response is significant (criterion met by either $\\mathrm{FEV}_{1}$ or $\\mathrm{FVC}$) and $C = 0$ otherwise.\n\nExpress the percent reversibility values as decimals without a percent sign and round them to four significant figures. Report your final result as a row vector $\\begin{pmatrix} r_{\\mathrm{FEV}_{1}}  r_{\\mathrm{FVC}}  C \\end{pmatrix}$, which is dimensionless. No units should appear in the final reported vector.",
            "solution": "The problem statement is evaluated and found to be valid. It is scientifically grounded in the principles of pulmonary function testing, well-posed with all necessary data and definitions, objective, and internally consistent. We can therefore proceed with a solution.\n\nThe objective is to compute the fractional reversibility for the forced expiratory volume in one second ($\\mathrm{FEV}_{1}$) and the forced vital capacity ($\\mathrm{FVC}$), and then to classify the overall bronchodilator response based on the American Thoracic Society/European Respiratory Society (ATS/ERS) criteria.\n\nLet the pre-bronchodilator values be denoted with the subscript 'pre' and post-bronchodilator values with 'post'. The given data are:\n- $\\mathrm{FEV}_{1, \\text{pre}} = 1.80\\,\\mathrm{L}$\n- $\\mathrm{FVC}_{\\text{pre}} = 3.50\\,\\mathrm{L}$\n- $\\mathrm{FEV}_{1, \\text{post}} = 2.06\\,\\mathrm{L}$\n- $\\mathrm{FVC}_{\\text{post}} = 3.78\\,\\mathrm{L}$\n\nThe final result is to be presented as a row vector $\\begin{pmatrix} r_{\\mathrm{FEV}_{1}}  r_{\\mathrm{FVC}}  C \\end{pmatrix}$, where $r_{\\mathrm{FEV}_{1}}$ and $r_{\\mathrm{FVC}}$ are the fractional reversibilities (rounded to four significant figures) and $C$ is the classification code.\n\n**Task 1: Compute the percent reversibility (fractional change)**\n\nThe fractional change, which we denote by $r$, is defined as $\\frac{\\text{post} - \\text{pre}}{\\text{pre}}$.\n\nFor $\\mathrm{FEV}_{1}$, the absolute change is:\n$$\n\\Delta_{\\text{abs, FEV}_1} = \\mathrm{FEV}_{1, \\text{post}} - \\mathrm{FEV}_{1, \\text{pre}} = 2.06\\,\\mathrm{L} - 1.80\\,\\mathrm{L} = 0.26\\,\\mathrm{L}\n$$\nThe fractional change for $\\mathrm{FEV}_{1}$ is:\n$$\nr_{\\mathrm{FEV}_{1}} = \\frac{\\Delta_{\\text{abs, FEV}_1}}{\\mathrm{FEV}_{1, \\text{pre}}} = \\frac{0.26}{1.80} = 0.14444...\n$$\nRounding to four significant figures, we get $r_{\\mathrm{FEV}_{1}} = 0.1444$.\n\nFor $\\mathrm{FVC}$, the absolute change is:\n$$\n\\Delta_{\\text{abs, FVC}} = \\mathrm{FVC}_{\\text{post}} - \\mathrm{FVC}_{\\text{pre}} = 3.78\\,\\mathrm{L} - 3.50\\,\\mathrm{L} = 0.28\\,\\mathrm{L}\n$$\nThe fractional change for $\\mathrm{FVC}$ is:\n$$\nr_{\\mathrm{FVC}} = \\frac{\\Delta_{\\text{abs, FVC}}}{\\mathrm{FVC}_{\\text{pre}}} = \\frac{0.28}{3.50} = 0.08\n$$\nTo express this with four significant figures, we must add trailing zeros, giving $r_{\\mathrm{FVC}} = 0.08000$.\n\n**Task 2: Classify the overall bronchodilator response**\n\nThe ATS/ERS guideline states that a response is significant if, for either $\\mathrm{FEV}_{1}$ or $\\mathrm{FVC}$, there is both an absolute increase of at least $0.20\\,\\mathrm{L}$ and a relative increase of at least $0.12$ (or $12\\%$). We check this composite criterion for each parameter.\n\n*   **Analysis for $\\mathrm{FEV}_{1}$:**\n    1.  Absolute change: $\\Delta_{\\text{abs, FEV}_1} = 0.26\\,\\mathrm{L}$. Is $0.26 \\ge 0.20$? Yes.\n    2.  Relative change: $r_{\\mathrm{FEV}_{1}} \\approx 0.1444$. Is $0.1444 \\ge 0.12$? Yes.\n    Since both conditions are met for $\\mathrm{FEV}_{1}$, the criterion for a significant response is satisfied by the change in $\\mathrm{FEV}_{1}$.\n\n*   **Analysis for $\\mathrm{FVC}$:**\n    1.  Absolute change: $\\Delta_{\\text{abs, FVC}} = 0.28\\,\\mathrm{L}$. Is $0.28 \\ge 0.20$? Yes.\n    2.  Relative change: $r_{\\mathrm{FVC}} = 0.08$. Is $0.08 \\ge 0.12$? No.\n    Since the condition for relative change is not met for $\\mathrm{FVC}$, the criterion for a significant response is *not* satisfied by the change in $\\mathrm{FVC}$.\n\nThe overall response is classified as significant if the criterion is met by *either* $\\mathrm{FEV}_{1}$ *or* $\\mathrm{FVC}$. As the $\\mathrm{FEV}_{1}$ response meets the criteria, the overall response is significant. Therefore, the classification code is $C = 1$.\n\n**Final Result Assembly**\nThe components of the final row vector are:\n- $r_{\\mathrm{FEV}_{1}} = 0.1444$\n- $r_{\\mathrm{FVC}} = 0.08000$\n- $C = 1$\n\nThe resulting vector is $\\begin{pmatrix} 0.1444  0.08000  1 \\end{pmatrix}$.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 0.1444  0.08000  1 \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "Once persistent airflow limitation is confirmed, classifying the severity of COPD is essential for prognosis and initial management strategies. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) provides a standardized spirometric framework for this purpose based on the post-bronchodilator forced expiratory volume in one second ($\\mathrm{FEV}_1$). This exercise  challenges you to apply the GOLD criteria to grade the severity of airflow limitation, connecting a quantitative lung function parameter to a clinical measure of disease severity.",
            "id": "4970314",
            "problem": "A clinician in a lower-middle-income country evaluates an adult patient with suspected chronic obstructive pulmonary disease (COPD; chronic obstructive pulmonary disease). Post-bronchodilator (BD; bronchodilator) spirometry demonstrates persistent airflow limitation with a ratio of forced expiratory volume in one second to forced vital capacity ($FEV_{1}/FVC$) equal to $0.62$. The patient’s predicted forced expiratory volume in one second ($FEV_{1}^{pred}$) is $2.6$ liters, and the measured post-bronchodilator $FEV_{1}$ is $1.1$ liters. Using the standardized spirometric grading framework of the Global Initiative for Chronic Obstructive Lung Disease (GOLD; Global Initiative for Chronic Obstructive Lung Disease), start from core definitions of spirometric prediction and grading to determine the patient’s GOLD spirometric grade ($1$–$4$) as a single integer by computing the proportion of predicted $FEV_{1}$ achieved and mapping it to the spirometric grade categories. Then, based on the meaning of that grade, explain in words the clinical implications for disease severity, symptom burden, exacerbation risk, and typical resource needs in a global health context. Report only the grade as your final numerical answer. No rounding is required. Express the final answer as the integer grade only (no units).",
            "solution": "The problem is subjected to validation before proceeding to a solution.\n\n**Step 1: Extract Givens**\nThe following data and conditions are explicitly provided in the problem statement:\n*   Diagnosis context: Chronic Obstructive Pulmonary Disease (COPD).\n*   Spirometric ratio: Post-bronchodilator (BD) forced expiratory volume in one second to forced vital capacity, $FEV_1/FVC = 0.62$.\n*   Predicted forced expiratory volume in one second: $FEV_{1}^{pred} = 2.6$ liters.\n*   Measured post-bronchodilator forced expiratory volume in one second: Post-BD $FEV_1 = 1.1$ liters.\n*   Required framework: Global Initiative for Chronic Obstructive Lung Disease (GOLD) standardized spirometric grading.\n*   Tasks:\n    1.  Compute the proportion of predicted $FEV_1$.\n    2.  Map this proportion to determine the patient's GOLD spirometric grade ($1$–$4$).\n    3.  Explain the clinical implications of the determined grade.\n    4.  Report only the integer grade as the final answer.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is assessed for scientific grounding, being well-posed, and objectivity.\n\n*   **Scientifically Grounded:** The problem is based on the established, internationally recognized GOLD guidelines for the diagnosis and management of COPD. The use of spirometric parameters such as $FEV_1$, $FVC$, and their ratio is the standard of care in pulmonology. The provided numerical values ($FEV_1/FVC = 0.62$, $FEV_1 = 1.1$ L, $FEV_{1}^{pred} = 2.6$ L) are clinically plausible for a patient with significant airflow obstruction.\n*   **Well-Posed:** The problem is well-posed. It provides all the necessary data to perform the classification according to the specified GOLD framework. The framework itself is a deterministic classification algorithm, which ensures a unique solution (a single integer grade) exists.\n*   **Objective:** The problem is stated using precise, objective medical terminology. The task is a direct application of a quantitative, standardized clinical protocol, free of subjective interpretation.\n\n**Step 3: Verdict and Action**\nThe problem is deemed **valid**. It is scientifically sound, contains sufficient and consistent information, and is structured to permit a unique, verifiable solution. A full solution will be provided.\n\n**Solution Derivation**\nThe determination of the patient's GOLD spirometric grade proceeds in three steps: confirmation of the COPD diagnosis based on the $FEV_1/FVC$ ratio, calculation of the percent predicted $FEV_1$ to assess the severity of airflow limitation, and mapping this percentage to the GOLD grading scale.\n\nFirst, the diagnosis of COPD must be spirometrically confirmed. The GOLD guidelines define COPD by the presence of persistent airflow limitation, which is established when the post-bronchodilator ratio of $FEV_1$ to $FVC$ is less than $0.70$.\nThe given value is:\n$$ \\frac{FEV_1}{FVC} = 0.62 $$\nSince $0.62  0.70$, the criterion for persistent airflow limitation is met, and a diagnosis of COPD is confirmed.\n\nSecond, the severity of airflow limitation is graded based on the post-bronchodilator $FEV_1$ expressed as a percentage of the predicted value. The percentage of predicted $FEV_1$, denoted as $FEV_1\\%_{pred}$, is calculated as:\n$$ FEV_1\\%_{pred} = \\frac{\\text{Post-BD } FEV_1}{FEV_{1}^{pred}} \\times 100\\% $$\nUsing the provided values:\n*   Post-BD $FEV_1 = 1.1$ L\n*   $FEV_{1}^{pred} = 2.6$ L\n\nThe calculation is:\n$$ FEV_1\\%_{pred} = \\frac{1.1}{2.6} \\times 100\\% $$\nThis fraction simplifies to:\n$$ \\frac{11}{26} \\times 100\\% \\approx 42.307...\\% $$\nFor the purpose of classification, we use this value of approximately $42.3\\%$.\n\nThird, this calculated percentage is mapped to the GOLD spirometric grading system. For patients with a confirmed diagnosis of COPD (i.e., post-BD $FEV_1/FVC  0.70$), the grades are defined as follows:\n*   **GOLD 1 (Mild):** $FEV_1 \\ge 80\\%$ predicted\n*   **GOLD 2 (Moderate):** $50\\% \\le FEV_1  80\\%$ predicted\n*   **GOLD 3 (Severe):** $30\\% \\le FEV_1  50\\%$ predicted\n*   **GOLD 4 (Very Severe):** $FEV_1  30\\%$ predicted\n\nThe patient's calculated $FEV_1\\%_{pred}$ is approximately $42.3\\%$. We check which category this value falls into:\nThe condition for GOLD 3 is $30\\% \\le FEV_1\\%_{pred}  50\\%$.\nSince $30 \\le 42.3  50$, the patient's airflow limitation is classified as **GOLD 3**.\n\n**Clinical Implications of GOLD Grade 3**\nAs requested, the clinical implications of a GOLD 3 grade are explained below.\n*   **Disease Severity:** This grade corresponds to **severe** airflow limitation. The patient's ability to exhale air quickly is substantially impaired, indicating significant lung damage.\n*   **Symptom Burden:** Patients at this stage typically experience a high symptom burden. This includes persistent and disabling dyspnea (shortness of breath) even with minor exertion, a chronic productive cough, and fatigue, all of which significantly degrade quality of life and limit daily activities.\n*   **Exacerbation Risk:** The risk of exacerbations—acute episodes of worsening symptoms that may require hospitalization—is significantly elevated in patients with GOLD 3 disease. Frequent exacerbations accelerate the decline in lung function and increase mortality risk.\n*   **Resource Needs in a Global Health Context:** In a lower-middle-income country, managing a patient with GOLD 3 COPD presents substantial challenges. Essential resources include consistent access to long-acting inhaled medications (often combination therapy like LABA/LAMA), which can be prohibitively expensive. Pulmonary rehabilitation, a highly effective non-pharmacological intervention, is rarely available. The high risk of exacerbations places a heavy burden on fragile health systems, requiring emergency care, potential hospitalization, and access to oxygen, antibiotics, and corticosteroids. If the patient develops chronic hypoxemia, the need for long-term oxygen therapy introduces further logistical and financial hurdles, such as the cost of an oxygen concentrator and the need for a reliable electricity supply.\n\nThe final numerical answer is the integer representing the GOLD grade.",
            "answer": "$$\n\\boxed{3}\n$$"
        },
        {
            "introduction": "Modern COPD management has evolved beyond simple spirometric grades to a more comprehensive assessment that guides therapeutic decisions. The current GOLD strategy integrates symptom burden, exacerbation history, and biomarkers like blood eosinophil counts to personalize treatment, particularly when considering the addition of inhaled corticosteroids (ICS). This problem  simulates a real-world clinical decision, requiring you to synthesize multiple data points to correctly classify a patient and justify an evidence-based escalation in therapy.",
            "id": "4798539",
            "problem": "A patient with Chronic Obstructive Pulmonary Disease (COPD) presents for follow-up after an acute event. Their post-bronchodilator forced expiratory volume in $1$ second ($FEV_1$) is $55\\%$ of predicted, their COPD Assessment Test (CAT) score is $12$, they have had $1$ hospitalization for a COPD exacerbation in the past $12$ months, and their peripheral blood eosinophil count is $320\\,\\text{cells}/\\mu\\text{L}$. The patient is currently maintained on dual long-acting bronchodilator therapy with a long-acting beta-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), and uses a short-acting bronchodilator as needed.\n\nUsing the following fundamental and widely accepted clinical bases:\n- Post-bronchodilator airflow limitation severity grading by $FEV_1$ percent predicted: Grade $1$ ($\\ge 80\\%$), Grade $2$ ($50$–$79\\%$), Grade $3$ ($30$–$49\\%$), Grade $4$ ($30\\%$).\n- Symptom burden categorization using the COPD Assessment Test (CAT): a score $\\ge 10$ indicates high symptom burden.\n- Exacerbation risk stratification by history in the prior year: high risk is defined by $\\ge 2$ moderate exacerbations or $\\ge 1$ exacerbation leading to hospitalization.\n- The Global Initiative for Chronic Obstructive Lung Disease (GOLD) grouping framework for initial and follow-up pharmacologic treatment: patients with high symptom burden and high exacerbation risk (including $\\ge 1$ hospitalization) are assigned to the high-risk group, termed Group E.\n- Blood eosinophil thresholds as a biomarker for inhaled corticosteroid (ICS) responsiveness in COPD exacerbation prevention: $\\ge 300\\,\\text{cells}/\\mu\\text{L}$ strongly favors benefit from adding ICS; $100$–$300\\,\\text{cells}/\\mu\\text{L}$ suggests potential benefit particularly if exacerbations persist; $100\\,\\text{cells}/\\mu\\text{L}$ generally predicts limited benefit and increased risk of pneumonia with ICS.\n\nWhich option best classifies this patient and justifies the next step in maintenance therapy escalation?\n\nA. GOLD airflow limitation Grade $2$ and Group E; escalate to triple therapy with LABA/LAMA/inhaled corticosteroid (ICS) because $1$ hospitalization confers high exacerbation risk and eosinophils $\\ge 300\\,\\text{cells}/\\mu\\text{L}$ predict ICS benefit.\n\nB. GOLD Group B; continue dual bronchodilator therapy (LABA/LAMA) and avoid ICS because $FEV_1 = 55\\%$ is only moderate obstruction.\n\nC. GOLD Group E; escalate to roflumilast and chronic macrolide, and avoid ICS because eosinophils $100\\,\\text{cells}/\\mu\\text{L}$ predict no benefit.\n\nD. GOLD Group B; start ICS/LABA (without LAMA) because eosinophils $\\ge 300\\,\\text{cells}/\\mu\\text{L}$ mandate ICS irrespective of exacerbation risk.\n\nE. GOLD airflow limitation Grade $2$ and Group E; escalate to triple therapy only if $FEV_1  30\\%$, otherwise maintain LABA/LAMA despite hospitalization.",
            "solution": "The derivation proceeds from established definitions and risk stratification principles rather than treatment recipes.\n\nFirst, determine airflow limitation severity from $FEV_1$ percent predicted. The patient’s $FEV_1 = 55\\%$ of predicted. By the accepted grading scheme, Grade $2$ corresponds to $50$–$79\\%$. Therefore, airflow limitation is GOLD Grade $2$.\n\nSecond, quantify symptom burden using the COPD Assessment Test. A CAT score $\\ge 10$ indicates high symptom burden. The patient’s $CAT = 12$, so they have high symptom burden.\n\nThird, stratify exacerbation risk by prior-year history. High risk is defined by $\\ge 2$ moderate exacerbations or $\\ge 1$ exacerbation requiring hospitalization. The patient has had $1$ hospitalization, which alone places them in the high-risk category.\n\nFourth, apply the Global Initiative for Chronic Obstructive Lung Disease grouping framework. Patients with high symptoms (CAT $\\ge 10$) and high exacerbation risk (including $\\ge 1$ hospitalization) are placed in Group E, which emphasizes exacerbation prevention. Note that GOLD’s symptom and risk-based grouping (A/B/E) is distinct from $FEV_1$ grade; therapy is guided primarily by symptoms and exacerbation risk rather than $FEV_1$ alone.\n\nFifth, assess the biomarker-based likelihood of benefit from adding inhaled corticosteroid. Blood eosinophil count $\\ge 300\\,\\text{cells}/\\mu\\text{L}$ is a strong predictor of reduction in exacerbations with ICS addition. At $320\\,\\text{cells}/\\mu\\text{L}$, this patient is within the range where ICS is expected to confer meaningful benefit. Although inhaled corticosteroids carry a pneumonia risk, in patients with high exacerbation risk and eosinophils $\\ge 300\\,\\text{cells}/\\mu\\text{L}$, the net benefit typically favors ICS addition.\n\nFor a patient already on LABA/LAMA with a recent hospitalization and eosinophils $\\ge 300\\,\\text{cells}/\\mu\\text{L}$, escalation to triple therapy (LABA/LAMA/ICS) is indicated to reduce exacerbations, aligned with biomarker-guided therapy and high-risk grouping.\n\nOption-by-option analysis:\n\nA. “GOLD airflow limitation Grade $2$ and Group E; escalate to triple therapy with LABA/LAMA/ICS because $1$ hospitalization confers high exacerbation risk and eosinophils $\\ge 300\\,\\text{cells}/\\mu\\text{L}$ predict ICS benefit.” This correctly identifies $FEV_1 = 55\\%$ as Grade $2$, recognizes CAT $\\ge 10$ and $1$ hospitalization as placing the patient in Group E, and uses the eosinophil threshold to justify ICS addition. The recommended escalation to triple therapy is consistent with high-risk, high-eosinophil COPD management. Verdict: Correct.\n\nB. “GOLD Group B; continue dual bronchodilator therapy (LABA/LAMA) and avoid ICS because $FEV_1 = 55\\%$ is only moderate obstruction.” This misclassifies the patient as Group B by ignoring the $1$ hospitalization, which defines high risk and thus Group E. It also improperly uses $FEV_1$ severity to steer therapy, whereas exacerbation risk and symptoms should guide escalation. Verdict: Incorrect.\n\nC. “GOLD Group E; escalate to roflumilast and chronic macrolide, and avoid ICS because eosinophils $100\\,\\text{cells}/\\mu\\text{L}$ predict no benefit.” While roflumilast and macrolides may be considered in select high-risk patients (e.g., chronic bronchitis, frequent exacerbations), the rationale given is factually wrong for this patient: eosinophils are $320\\,\\text{cells}/\\mu\\text{L}$, not $100\\,\\text{cells}/\\mu\\text{L}$. With eosinophils $\\ge 300\\,\\text{cells}/\\mu\\text{L}$, ICS should be favored. Verdict: Incorrect.\n\nD. “GOLD Group B; start ICS/LABA (without LAMA) because eosinophils $\\ge 300\\,\\text{cells}/\\mu\\text{L}$ mandate ICS irrespective of exacerbation risk.” This misclassifies the patient as Group B (ignoring the hospitalization), and suggests removing LAMA in a high-symptom patient, which is not appropriate. In COPD, bronchodilation is foundational, and in high-risk patients with elevated eosinophils, triple therapy rather than ICS/LABA alone is preferred. ICS benefit is context-dependent and does not “mandate” ICS irrespective of risk; it is guided by exacerbation profile and eosinophils. Verdict: Incorrect.\n\nE. “GOLD airflow limitation Grade $2$ and Group E; escalate to triple therapy only if $FEV_1  30\\%$, otherwise maintain LABA/LAMA despite hospitalization.” This wrongly ties escalation to $FEV_1$ thresholds. GOLD treatment recommendations prioritize exacerbation risk and biomarkers over $FEV_1$ cutoffs for ICS decisions. With $1$ hospitalization and eosinophils $\\ge 300\\,\\text{cells}/\\mu\\text{L}$, triple therapy is indicated regardless of $FEV_1$ being $\\ge 30\\%$. Verdict: Incorrect.\n\nTherefore, the best classification and escalation decision is given in option A.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}